on VVardis AG
VVardis Secures Apollo Investment, Achieves Unicorn Status
On April 27, 2026, vVardis Holding AG, a Swiss dental medtech company, announced a strategic investment from Apollo-managed funds. This investment supports the expansion of their non-invasive Curodont™ technology, which treats tooth decay without drilling. vVardis now ranks among Europe's top healthcare unicorns.
Founded by Drs. Haley and Goly Abivardi, vVardis is revolutionizing cavity treatment. Since its U.S. launch, Curodont™ has been implemented in 20% of dental practices, treating around 3 million teeth. The firm plans further expansion in the U.S. and Europe, backed by clinical studies validating their innovative approach.
The investment from Apollo strengthens vVardis' market presence, allowing it to broaden its reach and sustain its growth across key markets. The terms of the deal remain undisclosed, but the investment is key to advancing vVardis' mission of offering non-invasive dental solutions.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VVardis AG news